Avexa Limited Reaches First Critical Evaluation Point for ATC's Phase III Trial
Published: Mar 25, 2009
MELBOURNE, Australia--(BUSINESS WIRE)--Avexa Limited (ASX:AVX) today announced that the last patient enrolled in the initial two dose phase of the apricitabine (ATC) Phase III trial has passed the week 16 time point. This significant event triggers the start of the data analysis for the Week 16 results. The company is expecting to announce the results in the second quarter of 2009.